Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit). The main questions to answer are:
Full description
This clinical trial will enroll 100 participants, randomized 2:1 (AON-D21:placebo).
Participants diagnosed with severe community-acquired pneumonia of bacterial or viral origin requiring admission to an intensive care unit or similar setting, will receive either AON-D21 or placebo intravenous infusions for up to 10 days.
In addition, participants will receive standard of care as per local guidelines.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Antonio Perez, MD; Axel Vater, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal